Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

EXHIBIT 99.1 Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations Company Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Brand Building Capabilities that are Delivering Results Solid Execution Amid Challenging Market Consumption Trends Reaffirms Full Year 2025 Adj. EPS Target Range of $2.90 - $3.10 Second Quarter 2025 YoY Highlights: Secon ...

Company Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Brand Building Capabilities that are Delivering Results Solid Execution Amid Challenging Market Consumption Trends Reaffirms Full Year 2025 Adj. EPS Target Range of $2.90 - $3.10 DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Second Quarter 2025 YoY Highlights: Second Quarter 2025 YoY Segment Highlights: Consumer Self-Care ...

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 36% increase from the current trading price of $26.96 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 11.3% increase, while the highest suggests a 55.8% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are increasingly optimistic about PRGO's earnings prospects, as evidenced by upward revisions in EPS estimates [11] - The Zacks Consensus Estimate for the current year has risen by 0.3% over the past month, with one estimate increasing and no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Core Viewpoint - Perrigo Company plc (PRGO) is set to report its second-quarter 2025 earnings on August 6, with expectations of sales at $1.08 billion and earnings per share (EPS) at 59 cents, following a previous earnings surprise of 7.14% [1][7]. Group 1: Upcoming Earnings Expectations - The Zacks Consensus Estimate for sales in the Consumer Self Care Americas (CSCA) segment is $636 million, while the model estimate is $641 million. For the Consumer Self Care International (CSCI) segment, the estimates are $445 million and $439 million, respectively [3]. - Sales in the second quarter are anticipated to be affected by exited businesses, product line reductions, and unfavorable currency movements [2][7]. Group 2: Strategic Developments - Investors are looking for updates on the deal with KKR-backed Kairos Bidco AB regarding the sale of Perrigo's Dermacosmetics-branded business for up to €327 million, as well as insights on the expected impact of macroeconomic pressures in future quarters [4][7]. Group 3: Earnings Performance History - Perrigo has shown a decent earnings performance over the last four quarters, beating estimates in three of those quarters and missing once, resulting in an average surprise of 4.36% [5].

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12th at 9:00 AM EDT [1]

Core Viewpoint - Perrigo Company plc is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1] Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products with over a century of experience in delivering high-quality health and wellness solutions primarily in North America and Europe [3] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering accessible self-care solutions that do not require a prescription [3] Business Model - Perrigo's business model is characterized by its complementary businesses, where cash-generative store brand private label offerings support investments in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [4]

Shares of Perrigo (PRGO) have gained 2.9% over the past four weeks to close the last trading session at $27.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.67 indicates a potential upside of 35.4%.The average comprises three short-term price targets ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11. While the lowest estimate indicates a ...

Company Overview - Perrigo Company plc, based in Dublin, Ireland, was formed from the merger of Perrigo Company and Elan Corporation in December 2013, focusing on over-the-counter (OTC) markets and wellness solutions [12] - The company has a diversified revenue stream and operates in segments designed to enhance individual well-being [12] Investment Ratings - Perrigo is currently rated as a 2 (Buy) on the Zacks Rank, with a VGM Score of B, indicating a favorable investment outlook [12] - The company has a Momentum Style Score of B, with shares increasing by 2.9% over the past four weeks [13] Earnings Estimates - Two analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.04 to $3.04 per share [13] - Perrigo has an average earnings surprise of +4.4%, suggesting a positive trend in earnings performance [13] Investment Considerations - With a solid Zacks Rank and strong Momentum and VGM Style Scores, Perrigo is recommended for investors looking for potential growth opportunities [13]